Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESPRIT study of fluvoxamine for post-COVID fatigue
NL-OMON60493Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in post-COVID syndrome comparing Fluvoxamine with Placebo (2 arms). Primary endpoint: Fatigue severity at week 12. Started May 2026; status: recruiting.
02
Drugs
fluvoxamine
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on NL-OMON60493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60493.